Table 1.
Clinical and biochemical characteristics of the NAFLD and Control Groups
| NAFLD (n=85) | Control(n=40) | p | |
|---|---|---|---|
| Age | 45.2±10.2 | 41.9±9.6 | 0.179 |
| Gender, F/M | 53/32 | 22/18 | 0.173 |
| BMI, kg/m2 | 33.5±4.1 | 22.8±1.8 | <0.001 |
| ALT, IU/L | 90.4 [48.2-98.6] | 16.2 [10.0-29.7] | <0.001 |
| AST, IU/L | 62.2 [42.1-82.5] | 18.6 [12.4-23.1] | <0.001 |
| GGT, IU/L | 64.7 [24.7-69.5] | 13.4 [7.1-19.6] | <0.001 |
| HOMA-IR | 4.3 [2.9-6.1] | 1.8 [1.2-2.8] | <0.001 |
| CRP, mg/dL | 4.3 [2.6-7.7] | 1.4 [1.0-2.1] | <0.001 |
| Total cholesterol, | 198.7 [175.5-249.2] | 153.1 [130.4-179.7] | 0.002 |
| mg/dL | |||
| LDL, mg/dL | 121.9 [93.6-166.4] | 94.3 [81.4-124.3] | 0.031 |
| HDL, mg/dL | 43.4 [33.6-51.6] | 53.2 [47.6-59.5] | 0.022 |
| Triglyceride, mg/dL | 151.3 [100.4-218.6] | 79.7 [54.6-134.5] | 0.002 |
The values were shown as average±standard deviation for variables that had normal distribution; For non-normally distributed variables, the median; first and third quartile were shown in parentheses. BMI: Body mass index; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyltransferase; HOMA-IR: homeostasis model assessment of insulin resistance; CRP: C-reactive protein; LDL: low-density lipoprotein; HDL: high-density lipoprotein.